$16.34
-0.01 (-0.06%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MLTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional
Held by 18 tracked-famous managers (D. E. Shaw & Co., Inc., CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, Point72 Asset Management, L.P., Balyasny Asset Management L.P., +13 more) · FINRA short interest 6.6 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 6 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis SuppurativaNCT07007637Long-term safety and tolerability of sonelokimab: Adverse events (AEs) following treatment with sonelokimabOpen-label · Treatment | Phase 3 | Enrolling by invitation | Drug: Sonelokimab | Hidradenitis Suppurativa | 835 | 2028-06-13 | in 664 d | 2026-06-08 |
| A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic ArthritisNCT07223138Long-term safety and tolerability of sonelokimab:Open-label · Treatment | Phase 3 | Enrolling by invitation | Drug: Sonelokimab | Arthritis, Psoriatic | 1,560 | 2028-02-04 | in 534 d | 2026-06-11 |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugNCT06641076Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50)Randomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Sonelokimab, Placebo | Arthritis, Psoriatic | 960 | 2027-02-04 | in 169 d | 2026-08-12 |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate ResponseNCT06641089Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50)Randomized · Triple-masked · Treatment | Phase 3 | Recruiting | Drug: Sonelokimab, Placebo, Risankizumab | Arthritis, Psoriatic | 600 | 2027-01-15 | in 149 d | 2026-08-12 |
| An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)NCT06768671Pharmacokinetics (PK) of sonelokimab in adolescentsOpen-label · Treatment | Phase 3 | Active, not recruiting | Drug: Sonelokimab | Hidradenitis Suppurativa | 35 | 2026-09-28 | in 40 d | 2026-05-06 |
| An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an AutoinjectorNCT06994936Comparison of pharmacokinetics (PK) of an AI versus PFS administered single dose of sonelokimabRandomized · Open-label · Other | Phase 1 | Completed | Drug: Sonelokimab, Sonelokimab | Relative Bioequivalence | 120 | 2025-11-01actual | — | 2025-12-09 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT06411899Hidradenitis Suppurativa Clinical Response 75Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Sonelokimab, Placebo | Hidradenitis Suppurativa | 422 | 2025-09-02actual | — | 2026-08-12 |
| Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT06411379Hidradenitis Suppurativa Clinical Response 75Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Sonelokimab, Placebo | Hidradenitis Suppurativa | 418 | 2025-08-14actual | — | 2026-06-08 |
| Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic ArthritisNCT05640245Response Rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50)Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Sonelokimab, Placebo, Adalimumab | Arthritis, Psoriatic | 207 | 2023-09-05actual | — | 2024-09-05 |
| Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis SuppurativaNCT05322473Hidradenitis Suppurativa Clinical Response 75Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Sonelokimab (M1095), Adalimumab · Other: Placebo | Hidradenitis Suppurativa | 234 | 2023-05-09actual | — | 2024-05-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19